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12 
be determined by exercise testing preferentially with respiratory gas 
exchange measurements. In this thematic issue, three review articles 
are published with a common theme of the assessment of exercise 
performance in children with congenital heart disease, both operated 
and non-operated. 
    The first chapter is dedicated to new concepts in the assessment 
of exercise tolerance in children with CHD. In this contribution, 
a new assessment paradigm that optimizes the use of exercise test 
results to promote physically active lifestyles is recommended. 
The assessment of physical literacy and an expanded use of the 
data available from a maximal cardiopulmonary exercise test are 
discussed in this light. 
    Since exercise capacity can change in growing children, a second 
chapter describes the value of serial exercise testing in children with 
CHD. Regularly repeated assessments of an individual’s exercise 
function can therefore provide unique and valuable insights into the 
capabilities and cardiovascular health of patients with CHD. Serial 
exercise testing might as such provide important information both for 
the assessment of the current health status as for the estimation of the 
long term outcome of children with CHD. 
    And finally one contribution will demonstrate the usefulness of 
exercise testing in the clinical decision making regarding children 
with a left- to right shunt. Furthermore, in this review, the effects of 
abolishing left-to right shunt on exercise capacity, both early and late 
after closure will be summarized. 
    We hope that readers will enjoy this issue, obtain useful 
information, and be inspired with new ideas for the implementation 
and more expanded use of exercise testing in children with CHD. 
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EditoRial
Physical inactivity is considered as a cardiovascular risk factor in 
adults. Also in children, physical inactivity is often associated with 
disease. More specifically children with congenital heart disease 
(CHD) often were quiescent or did not perform the same activities as 
their healthy peers. 
    Exercise tolerance can be assessed by history taking or with 
questionnaires, but is has been shown that misclassifications were 
found by using these questionnaires with overestimation of up to 30% 
of the level of physical activity[1]. Therefore exercise tolerance has to 
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ABSTRACT
A left-to-right shunt lesion exists when blood from the left atrium, 
left ventricle, or aorta transits to the right atrium or its tributaries, the 
right ventricle, or the pulmonary artery. In these conditions blood 
from the systemic arterial circulation mixes with systemic venous 
blood. The presence of a left-to-right shunt results in a volume 
overload of one or more cardiovascular chambers or structures. 
Multiple factors influence the extent of flow through the shunt and its 
physiologic effects.
    If the shunt is significant, blood flow and pressure in the 
pulmonary circulation become abnormally high. At the same type 
the amount of blood which reaches the systemic circulation (cardiac 
output) can be reduced, particularly during exercise. Over time, there 
is progressive damage to the pulmonary vasculature endothelium and 
gradual development of irreversible pulmonary vascular changes and 
pulmonary hypertension. The resistance in the pulmonary circulation 
may ultimately exceed the systemic resistance with reversal of blood 
flow from the right side of the circulation to the left (Eisenmenger 
syndrome) evident as cyanosis either at rest or during exercise.
    Lesions resulting in left to right shunts include: (1) Atrial septal 
defect (ASD); (2) Ventricular septal defect (VSD); (3) Patent ductus 
arteriosus (PDA); (4) Large coronary artery fistulas.
    While wide consensus exists in the management of significant 
shunts, it is not always clear when and how it is time to intervene 
on smaller defects. We will review the evidence supporting a role of 
exercise testing in the assessment of children and adults with left-to-
right shunt and the effect of abolishing left-to right shunt on exercise 
capacity, both early and late after closure. No data is available in 
the literature on exercise capacity in patients with PDA or coronary 
artery fistulas. Therefore our work will focus on ASDs, which have 
been widely studied, and, to a lesser extent, VSDs.
© 2015 ACT. All rights reserved.
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ATRiAl SepTAl defeCTS pRopoSed
Atrial septal defects are the most common form of congenital heart 
defect and occur in 1 child in 1,500 live births[1]. Of the various types 
classified in base of the anatomic location, ostium secundum ASDs 
represent 6% to 10% of all cardiac anomalies. 
    In the setting of a large inter-atrial communication, a chronic 
left-to-right shunt creates a volume overload on the right-sided 
cardiac structures and results in dilation of the right atrium and right 
ventricle. The chronic volume overload causes dilation of the entire 
pulmonary vascular bed. Pulmonary blood flow is increased, often 
up to three to four times normal. However, the pulmonary artery 
pressure is only slightly increased, and in most patients, pulmonary 
resistance remains in the normal range. 
    Most infants and children with ASDs are asymptomatic. Rarely, 
ASDs are associated with poor growth, recurrent lower respiratory 
tract infection, and heart failure. Children with large left-to-right 
shunts are likely to complain of some fatigue and dyspnea. 
    The natural course of ASDs is relatively benign except for those 
with persistent significant left-right shunt. Typically, patients with 
smaller ASDs remain active and asymptomatic through early 
childhood, and many patients have lived into their fourth, fifth, 
sixth, and even seventh decades with ASDs of moderate size before 
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term after surgical closure without any impact on exercise capacity or 
onset of arrhythmias[7].
    Only one study, by Massin et al, compared the outcome of children 
who underwent percutaneous ASD closure versus open surgery. The 
study showed no difference in peak VO2 but underlined a higher 
prevalence of chronotropic incompetence in the surgical group, 
even though this didn’t affect overall exercise capacity[8]. In this 
setting chronotropic incompetence is thought to be secondary to the 
effect of the cannulation used to establish cardiopulmonary bypass. 
Previous studies showed a significant reduction in exercise tolerance 
in children with ASD[9] and failed to show a significant improvement 
after trans-catheter closure[9,10]. Reasons for that might be the fact 
that study cohorts were small and that the follow up was limited to 3 
months, when research in young adults suggests that the process of 
normalisation of exercise capacity can take significantly longer than 
3 months[11]. No data is currently available on long term outcome of 
percutaneous closure in children.
exeRCiSe ToleRAnCe in AdulT pATienTS 
TReATed foR ASd
At present ASDs accounts for up to 40% of congenital heart 
lesions detected in adults 40 years of age and older[12]. Despite high 
pulmonary blood flow and right heart volume overload, patients 
with uncomplicated ASD often report only minor subjective 
complaints and do not recognise their reduced exercise tolerance. 
This is evident from the fact that several studies have shown reduced 
exercise capacity even in asymptomatic patients[13,14]. Nakanishi and 
colleagues tested 18 adult ASD patients and found their peakVO2 
was impaired (21.6±5.6 mL/min/kg or 63.5±16.2% of predicted). 
They also observed that higher PAPm and higher Qp/Qs were related 
to lower exercise capacity[12]. Oelberg et al tested 10 adults with ASD 
and compared them to 10 matched healthy controls. Their patients 
were found to have reduced exercise performance, which could be 
associated with an abnormal increase in pulmonary artery pressure 
during exercise[15].
    In the past when only surgical procedures were available, only 
large ASDs would be advised for closure because they were 
considered likely to result over time in shunt reversal or heart failure. 
Adults with significant ASDs are advised to undergo surgical repair 
before the onset of pulmonary hypertension in order to increase 
longevity and limit the deterioration of functional capacity. Once 
pulmonary hypertension develops, irreversible right ventricular 
failure may result. However, it can be difficult to detect early stages 
of pulmonary vascular damage when pulmonary arterial pressures 
and pulmonary vascular resistance are still normal at rest but they can 
rise, instead of physiologically decrease, during exertion[16].
     Surgical series have shown discordant results on functional 
status following surgical ASD closure in adult patients, giving rise 
to concerns on the appropriate timing of intervention and patients 
selection. Fredriksen et al. compared exercise capacity in adults with 
congenital heart disease with healthy subjects and found that even 
patients with closed ASDs did not do as well as controls in the long 
term[17].  However, Helber et al showed a lack of improvement in 
exercise capacity early after surgical ASD closure in patients over 
the age of 40 years, but they suggested that the improvement in 
exercise capacity took place later as demonstrated by the complete 
normalisation observed 10 years after shunt closure[18]. They observed 
that the improvement in exercise tolerance didn’t correlate with the 
size of the shunt but it correlated inversely with mean pulmonary 
pressure before closure. Kobayashi et al reported a larger cohort and 
symptoms developed[2].
    Congestive heart failure rarely is found in the first decades of life, 
but it becomes more common with advancing age. The same can be 
said for the incidence of atrial arrhythmias with the associated risk of 
stroke and paradoxical embolism[1]. In a few patients (5-10%) with 
a secundum ASD, severe and irreversible hypertensive pulmonary 
vascular disease may develop[3].
    As cardiac catheterisation used to performed as a diagnostic step in 
many patients with an ASD, indication on closure was predominantly 
based on haemodynamic data, particularly the  extent of the ratio 
between pulmonary blood flow and systemic blood flow (Qp/Qs). 
It is generally accepted that elective closure of ASD is the treatment 
of choice if pulmonary-to-systemic blood flow ratio is >1.5. 
However, many children now do no undergo cardiac catheterisation 
as a diagnostic step and invasive criteria have been replaced by 
echocardiographic criteria. The main criteria for posing the indication 
to ASD closure is the presence of more than mild right heart 
dilatation or signs of increased right ventricular systolic pressure in 
the face of significant left-right shunt (which can also measured by 
echocardiography). Additional qualitative criteria are the presence of 
increased venous return from the pulmonary veins and dilatation of 
the main pulmonary artery.
    Elective surgical repair of ASDs has been a safe and simple 
operation in the hands of an experienced surgical team. It has been 
the first treatment of choice for children with large defects in the last 
50 years and there is a large body of medical research covering long 
term results. Since most ASDs are well tolerated in infancy and may 
spontaneously close, elective repair frequently has been deferred until 
the child is at least 4 years of age. 
    Trans-catheter techniques for closure of ostium secundum ASDs 
have been available for several years. In 1976, King et al reported 
the first trans-catheter closure of a secundum ASD in humans with 
a double-umbrella device[4]. The availability of non surgical ASD 
closure has led to an increase in the number of the defects being 
closed[5] and has perhaps also lowered the bar for some defects to 
be considered for closure. Trans-catheter closure has the advantage 
of avoiding the need for sternotomy, cardiopulmonary bypass and 
intensive care stay and facilitates rapid patient recovery when the 
anatomy of the defect is suitable. However still nowadays younger 
patients or those with very large defects or small/absent defect 
margins require surgical closure.
exeRCiSe ToleRAnCe in ChildRen TReATed 
foR ASd
Data are now available on long term follow-up of patients who 
underwent surgical ASD closure during childhood. Despite a clear 
improvement in the morbidity of these patients, there is still ongoing 
debate on whether children with ASD which undergo surgical closure 
can achieve the same life expectancy of healthy peers if treated 
timely. Cuypers et al recently published very long-term (30-41 
years) outcome after surgical ASD closure in childhood  and showed 
excellent survival and low morbidity. The general health and exercise 
capacity of the patients reported were comparable to the healthy 
Dutch population. They reported no pulmonary hypertension but 
persistent right ventricular dilation at magnetic resonance imaging 
despite a long follow-up from closure[6]. In the recent study by de 
Koning et al, exercise testing did not reveal differences between 
patients who underwent surgical ASD closure in childhood and 
healthy reference population. In line with Cuypers et al they found 
right ventricular end-systolic volume remained increased in the long 
Cervi E et al.  Exercise tolerance in children with a left to right shunt
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an increase in pulmonary vascular resistance.
    With large VSDs, a gradual decline of pulmonary vascular 
resistance usually occurs in the first few months of life, resulting 
in augmentation of the left-to-right shunt. The large blood volume 
handled by the left atrium results in left atrial and pulmonary venous 
hypertension. The increased return to the left side of the heart 
results in an enlarged left atrium and left ventricle as well as an 
increase in the left ventricular muscle mass. With the marked volume 
overload of the left ventricle, congestive heart failure is particularly 
likely to occur between the ages of 2 and 8 weeks. Compensatory 
mechanisms that allow the infant to adapt to this volume load include 
the Frank Starling effect, increased sympathetic cardiac stimulation, 
and myocardial hypertrophy. The rapidity of the development of 
myocardial hypertrophy is one of the major factors in the ability of an 
infant to compensate adequately for a VSD with a large left-to-right 
shunt.
    Excessive and high pressure pulmonary blood flow is associated 
with progressive pulmonary arterial vessel injury. Chronic injury 
associated with a large un-repaired VSD can result in a thickened 
adventitia, medial hypertrophy, and intimal injury resulting in 
pulmonary vascular obstructive disease[1]. Therefore, large VSDs 
with left-to-right shunt should undergo surgical repair within 1 year 
of age to prevent pulmonary vascular changes. Smaller defects can be 
followed up in time and a considerable portion is found to decrease in 
size and eventually spontaneously close[22,23]. The long term outcome 
of this latter group seems benign.
    When children with surgically closed VSDs or those with 
haemodynamically insignificant defects have undergone ECG 
exercise testing results have generally showed normal exercise 
capacity[23-26]. A small number of studies concentrated on 
cardiopulmonary exercise testing in patients with VSDs. Binkhorst et 
al. showed no difference in peak VO2 in patients after surgical VSD 
closure, small VSDs left untreated and healthy controls. Perrault at 
al. compared a small cohort of repaired VSD patients to patients with 
repaired tetralogy of Fallot, patients with repaired ASD and healthy 
controls and found peak VO2 values were within the normal range 
in patients with closed VSDs. In both the previously mentioned 
studies, peak heart rate was found to be lower in surgical treated VSD 
patients, which is consistent with previous evidence of chronotropic 
limitations after cardiopulmonary bypass surgery in different types of 
congenital cardiac defects[27,28]. 
    Moller et al described 44 patients (17 surgically closed 
ASD, 11 surgically closed VSD, 16 restrictive VSD considered 
haemodinamically not significant and thus left open) who underwent 
cardiopulmonary exercise testing and exercise echocardiography. 
They found reduced exercise capacity in all patients groups when 
compared to a control group comprising 88 healthy subjects. The 
authors observed an abnormal right ventricular systolic pressure 
response to exercise even in those patients who did not have any 
signs of increased pulmonary artery pressure at rest before closure. 
This finding was confined to VSD patients alone, either closed (5/11 
patients) or open (4/16 patients), whereas no ASD patients showed 
increased pulmonary pressure during exercise[29].
diSCuSSion
Patients with significant left-to-right shunt, particularly ASD 
patients, even if asymptomatic, have a significant exercise capacity 
limitation when compared to healthy controls[9,15]. Patients who are 
symptomatic, those with larger shunts and those with increased 
pulmonary artery pressure can be particularly limited.
stratified patients on the basis of the size of the shunt and the degree 
of pulmonary arterial hypertension. No peak VO2 improvement was 
shown in the group of patients with PAPm>30 mmHg, while those 
patients with significant shunts and lower pulmonary artery pressure 
did improve their exercise capacity following closure[19].
    The importance of finding abnormal and possibly exercise-
limiting elevations in pulmonary artery pressure during exercise 
in ASD might also be important in the decision making regarding 
the timing of surgical closure. Van de Bruaene et al demonstrated 
older patients who underwent closure later on in life had a good 
overall cardiopulmonary capacity but didn’t normalise pulmonary 
haemodinamics, which was shown by the lack of physiological 
decrease of pulmonary vascular resistance on exertion[16].
    In recent years trans-catheter closure has became widely available 
and the results have proven to be at lest as good as surgical closure 
in terms of mortality and functional capacity. Suchon et al compared 
the two techniques in an effort to demonstrate that, when dealing 
with favourable anatomy, percutaneous closure is a less costly option 
and guarantees the same results in the mid term. They demonstrated a 
low exercise capacity at baseline and a significant increase in oxygen 
uptake after both surgical and trans-catheter closure, as well as a 
significant decrease in minute ventilation/CO2 dioxide output. Their 
patients improved significantly their exercise capacity, irrespective 
of the actual method of closure, but patients with elevated right 
ventricular systolic pressures failed to normalise their peak VO2[20].
    Brochu et al assessed the effect of percutaneous ASD closure in 
37 asymptomatic or mildly symptomatic adults showing a significant 
and rapid improvement of exercise capacity and regression of right 
ventricular dilatation at 6 months. The improvement in exercise 
capacity was irrespective of age, functional class, right ventricular 
enlargement, or baseline exercise capacity[14]. 
    Jategaonkar et al reported a significant decrease in right ventricular 
end-diastolic diameter and significant improvements of NYHA 
functional class and peak VO2 at 3 months from ASD device closure 
in all age groups, even in patients over 60 years old. However, little 
is known about long-term results in those patients[21].
    Our group evaluated the impact of trans-catheter ASD closure on 
right ventricular remodelling and exercise capacity in asymptomatic 
adult patients with the aim of identifying the factors associated with a 
change in exercise capacity. We demonstrated that the improvement 
in peak VO2 is due to an improvement in peak O2 pulse. We also 
demonstrated that an increase in both left ventricular stroke volume 
and cardiac output due to a positive ventricular interaction is the 
mechanism leading to increased peak O2 pulse and peak VO2[13]. 
We also demonstrated that the improvement is not limited to the 6 
months period as a further cardiac remodelling and improvement 
in exercise capacity can be expected in the mid term[11,13]. Another 
observation from our group is that device ASD closure can quicken 
the time taken to recover from maximal exercise, which might also 
have positive implications for patients. 
VenTRiCulAR SepTAl defeCTS
Ventricular septal defects account for approximately a third of the 
congenital cardiac defects diagnosed at birth. The magnitude of the 
left-to-right shunt is related directly to the size of the defect and 
pulmonary vascular resistance. Small VSDs are those less than one 
third the size of the aortic root and which impose a high resistance 
to flow with a resultant large pressure drop between the left and 
the right ventricle. In this case, the left-to-right shunt is small, right 
ventricular systolic pressure is normal, and there is no tendency for 
???????????????? ??????????????????
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    Patients with ASD, like many other children with congenital heart 
defects, generally adapt to their limitation which is present since 
early infancy and describe themselves as asymptomatic, even when 
their exercise capacity is clearly reduced[13,29,30]. Therefore, indication 
for closure can not rely on symptoms which are generally late, when 
complications have already developing. There are no available 
longitudinal data on exercise capacity in untreated ASD patients 
but early cross-sectional evaluations suggested symptoms usually 
develop during adulthood and the natural history of the disease is not 
benign in the long term[3].
    While we agree on ASD closure when a large shunt is detected 
during childhood, debate is still ongoing in older patients with smaller 
shunts or large shunts that eventually caused borderline pulmonary 
vascular damage with slight and/or reversible raise in pulmonary 
arterial pressures. Age does not seem a determinant of the response 
to ASD closure as over 40 years old seem to improve their peak VO2 
in a similar fashion to those patients below 40 years of age[13,14]. Even 
though there is an association between change in peak VO2 and size 
of the left-to-right shunt, patients with smaller shunts (like those with 
a Qp/Qs <2) also show some clinically significant improvements in 
their exercise capacity after closure[13,14].
    After surgical closure right ventricular dimensions change 
dramatically and exercise capacity greatly improves. However, 
whereas in children exercise capacity gradually reaches normal 
values in the long term[7], peak VO2 fails to reach predicted values in 
adult patients with preoperative signs of pulmonary hypertension[20].
    Due to its less invasive nature with short recovery time and low 
morbidity and mortality, percutaneous closure has becoming the first 
choice treatment in older children and adults with a suitable anatomy. 
The first small studies on trans-catheter closure showed no significant 
difference in peak VO2 after closure[9,10]. Larger subsequent studies 
showed that percutaneous ASD closure led to an improvement in 
exercise capacity regardless of age at ASD closure[21] and symptoms, 
but proportional to the amount of left-to-right shunt and pulmonary 
artery pressure[11,19]. Data from our lab[13] have shown that the left-
to-right shunting of blood does not only cause pulmonary over-
circulation (both at rest and during exercise) but also causes a 
reduction in systemic perfusion, both at rest and during exercise. We 
also showed that the improvement in peak VO2 after ASD closure 
is a consequence of increased left ventricular stroke volume and 
cardiac output. ASD closure augments left ventricular filling, thereby 
increasing left ventricular preload, left ventricular end-diastolic 
diameter and ultimately left ventricular stroke volume. At the same 
time the right ventricle decreases in size, paradoxical septal motion 
disappears and ventricular interaction improves.
    Peak VO2 improvement was observed with both surgical and 
percutaneous closure series[8,20]. Improvements were as early as 3 
months post-op, particularly after percutaneous closure because of 
the reduced recovery time, but they appear to continue over time with 
further increase in exercise capacity in the mid-term[7,11]. However, 
postoperative exercise capacity was reported lower than in normal 
subjects[31] presumably because of low cardiac output during exercise 
due to reduced heart rate response during exercise[32], or a low level 
of daily physical activity after surgical closure of ASD which is 
observed also in children with other types of congenital heart disease. 
Furthermore an inappropriate response of the pulmonary vasculature 
to exercise may also have a large influence on postoperative exercise 
capacity.
    Studies looking at cardiopulmonary responses to exercise in 
VSD patients have shown mixed results with some studies showing 
some limitation in peak VO2 related to increased right ventricular 
systolic pressure during exercise whereas other studies have shown 
no evidence of significantly reduced exercise tolerance either when 
considering large VSDs after closure or small VSDs in natural 
history. However, all studies were of small size and therefore no 
generalisation can be made for the overall VSD population. Children 
with Down’s syndrome and congenital heart defects have a higher 
predisposition to develop pulmonary hypertension[33] and this is due 
to many different factors that can be controlled or modified only to 
a minor extent[34]. Therefore, exposure to long-standing increased 
left-to-right shunt flow where sheer stress on endothelium induces 
endothelial dysfunction followed by irreversible remodelling of 
pulmonary arteries, may have a worse effect in subjects with Down 
syndrome compared to non-syndromic children[35]. These children 
and young adults are therefore more likely to have their exercise 
capacity affected by changes in the pulmonary vasculature and 
should receive early treatment[29].
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ABSTRACT 
Cardiovascular function is an important determinant of exercise 
function. Formal exercise testing can therefore provide clinically 
useful, quantitative and objective insights into a patient’s 
cardiovascular status. Serial exercise studies evaluate the progress 
of an individual patient’s exercise function over a period of time and 
provide clinicians with a unique perspective upon the natural history 
of congenital heart disease. They can also provide quantitative, 
objective data regarding the functional impact of various clinical 
interventions and often shed light on important physiologic processes 
that otherwise might not be appreciated.
© 2015 ACT. All rights reserved.
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Why LongiTudinAL And SeRiAL STudieS?
Cross-sectional studies of exercise function, because they provide 
only a snapshot of a group of patients at a single point in time, 
leave clinicians with many unanswered questions. For instance, 
cross-sectional studies cannot determine whether a patient with 
poor exercise function has experienced a progressive decline over 
time, or has always had a similar degree of exercise dysfunction[1]. 
In the world of pediatric cardiology this issue is also complicated 
by the fact that the field has evolved rapidly over the past few 
decades. Innovations, both great and small, have dramatically 
affected the life expectancy and quality of life of patients with 
congenital heart disease. Researchers are therefore confronted by 
a clinical landscape that is always changing, in constant motion. 
Understanding the natural, or unnatural, history of individual 
congenital heart defects in this setting is therefore a complex affair 
and the inherent limitations of cross-sectional studies emerge as 
serious shortcomings. For example, if a study were to find that 
older subjects with a particular congenital heart defect performed 
less well than younger subjects, the study would be unable to 
unambiguously determine whether this observation was related to 
an era effect, i.e., less sophisticated cardiologic care available to the 
older subjects when they were young, or to a natural, time-related 
decline associated with the heart defect itself and unrelated to the 
medical advances achieved during the patients’ lifetime. Indeed, the 
snapshots that cross-sectional studies provide are often blurred and 
hard to interpret. 
    Longitudinal studies (which, for the purpose of this paper, will 
be defined as studies that observe the natural evolution of exercise 
function in the absence of an intervention, in contrast to the term 
“serial exercise studies”, which will refer to exercise tests performed 
before and after an intervention), on the other hand, evaluate the 
progress of individual patients over a period of time. They therefore 
can convey a more accurate and reliable picture of the natural history 
of congenital heart defects in the current era. The influence of era 
effects are also more readily appreciated and assessed.  
    The clinical importance of longitudinal exercise testing arises from 
the fact that the primary function of the cardiovascular system is to 
supply blood flow (and oxygen) in quantities sufficient to support 
the metabolic needs of the body.  This function is maximally stressed 
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illustrate these points, will now be briefly reviewed.  
    Helber et al studied the exercise function of 31 adult patients 
before and after surgical ASD repair. Prior to surgery, the patients’ 
exercise capacity was severely depressed (peak VO2 13.1 mL/kg/
min; ~50% of predicted). Four months post-operatively peak VO2 
increased minimally (13.6 mL/kg/min). However, when tested 10 
years post-op, peak VO2 had increased to normal levels (27.0 mL/kg/
min; ~95% predicted). Similar patterns were observed for the peak 
work rate and the VO2 at the ventilator anaerobic threshold. The lack 
of improvement in exercise function at the 4 month post-operative 
visit was thought to be due to the debilitation associated with the 
trauma of surgery and inactivity during the convalescent period.  The 
subsequent improvement in exercise function was attributed to a 
training effect that accompanied the resumption of normal physical 
activities.  These observations underscored the important interaction 
between the cardiovascular and skeletal muscle systems[9].
    In 2008, Meadows et al reported the results of serial exercise tests 
in 20 Fontan patients before and after fenestration closure. Although 
transcatheter Fontan fenestration closure had previously been shown 
to engender an acute increase in arterial oxygen saturation, the 
procedure was also known to be associated with an acute decrease 
in systemic cardiac output and oxygen delivery. The sum result 
of these physiologic changes upon exercise capacity of Fontan 
patients had never been examined. The authors found that, although 
baseline and peak-exercise arterial oxygen saturations improved 
significantly after fenestration closure, there was no change in peak 
VO2 (70.9±18.6% to 74.0±18.6%, p=NS), heart rate, or O2 pulse 
at peak exercise.  They explained these findings by noting that, at 
peak exercise, oxygen uptake by the lungs is dependent upon the 
mixed venous oxygen saturation and the pulmonary blood flow, 
which in turn is determined the mean pulmonary artery pressure, 
the pulmonary vascular resistance and the mean left atrial pressure. 
Because oxygen extraction is maximized at peak exercise (and mixed 
venous oxygen saturation falls to the same low level, whether or not 
a fenestration is present), and because fenestration closure is unlikely 
to have a large impact upon the Fontan patient’s pulmonary vascular 
resistance, pulmonary artery or left atrial pressure at peak exercise, 
fenestration closure is unlikely to have a dramatic effect upon peak 
VO2. The authors also observed, however, that the VE/VCO2 slope fell 
in 20/20 patients after fenestration closure, and the end tidal pCO2 
at the VAT rose in 19/20 patients.  This observation was attributed 
to the reduction in right to left shunting CO2-rich blood following 
fenestration closure[10].
    In contrast to the observations in Fontan patients, Rhodes et al 
reported that the peak VO2 of a patient with a large physiologic right 
to left shunt secondary to a pulmonary AV fistula improved following 
transcatheter occlusion of the fistula. In that case, the patent fistula 
impeded blood flow to the alveoli during exercise. Occlusion of the 
fistula allowed more blood to flow to the alveoli at peak exercise 
and thereby permitted greater oxygen uptake by the lungs at peak 
exercise. As with the Fontan patients, the elimination of the CO2-
rich right to left shunt blood also engendered a decline in the VE/VCO2 
slope and an increase in end tidal pCO2[11].
    The results of serial exercise tests in tetralogy of Fallot patients 
undergoing pulmonary valve replacement surgery have been mixed. 
Some have found an improvement in exercise function[12], others 
have not[13-15]. The discrepancies are probably due, in part, to the 
time interval between the surgery and the post-operative exercise 
test; improvements in exercise function may not be observed until 
the deconditioning associated with the surgery and convalescence is 
reversed.
during physical activity (i.e., exercise)[2]. Longitudinal assessments 
of an individual’s exercise function can therefore provide unique 
and valuable insights into the capabilities and cardiovascular health 
of patients with congenital heart disease. These considerations also 
apply serial exercise studies, which can provided clinicians with 
objective, quantitative data regarding the effect of a cardiovascular 
intervention upon a patient’s exercise function.
TeChniCAL iSSueS ReLATed To 
LongiTudinAL STudieS And SeRiAL 
exeRCiSe TeSTS
Body size and exercise capacity change rapidly during the pediatric 
years. These changes are especially dramatic during puberty. 
Furthermore, although gender-related differences in exercise capacity 
exist prior to puberty, these differences become more pronounced 
during and after the pubertal years. Exercise capacity also continues 
to change during adulthood. On average, peak VO2 declines by 
~0.7%/year after age 21[3]. Consequently, when comparing exercise 
test data from studies performed on an individual at different 
ages, the potential implications of these natural changes must be 
borne in mind.  Because prediction equations (ideally) take these 
considerations into account, for peak VO2 and related variables [e.g., 
the oxygen pulse and the VO2 at the ventilatory anaerobic threshold 
(VAT)], it is usually best to express data as a percentage of predicted 
values, especially when the studies include patients in the pediatric 
and adolescent age groups[2].  It must be noted, however, that the most 
commonly employed pediatric prediction equations were derived 
more than three decades ago in a group of 109 normal subjects[4]. 
More recent studies have raised concerns about the applicability of 
these equations in the current era[5]. Some have also suggested that 
account should be taken of seasonal changes in exercise function[6].
    Other exercise-test variables may also vary with age.  For instance, 
Giardini et al recently reported that the VE/VCO2 slope declines during 
the pediatric years and then rises again during adulthood.  When 
interpreting data from longitudinal studies, account must be taken of 
these natural changes as well[7].
    Patient effort can have a dramatic effect upon peak-exercise 
variables. Consequently, when comparing peak-exercise data from 
serial exercise tests, it is essential to ensure that an adequate effort 
was expended on both tests. Otherwise, the potential confounding 
effects of variable patient effort will make comparison of serial 
peak-exercise data uninterpretable or misleading. To achieve this 
goal, physiologic criteria for an adequate effort should be applied. 
Acceptable criteria include a respiratory exchange ratio (RER) ≥1.09 
at peak exercise and/or a peak heart rate >85% of predicted at peak 
exercise (in the absence of a tachyarrhythmia)[2]. Some investigators 
claim that the anaerobic metabolic pathways are less developed in 
children and therefore suggest that, for young subjects, a lower RER 
may be a more appropriate threshold[8]. Of course, issues related to 
patient effort do not apply to data derived from submaximal exercise, 
e.g., the VO2 at the VAT and the VE/VCO2 slope.
CLiniCAL uTiLiTy of SeRiAL exeRCiSe TeSTS
Serial exercise tests can provide quantitative, objective data regarding 
the benefits and/or effectiveness of therapeutic interventions that are 
undertaken for patients with congenital heart disease. The results 
of these studies are sometimes surprising and can reveal important 
physiologic phenomena that might otherwise be overlooked. A 
few studies selected from the pediatric cardiology literature, which 
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focused upon the longitudinal exercise function of patients with 
congenital heart disease.  In a study of 98 Fontan patients with serial 
exercise data, Fernandes et al found that the %predicted peak VO2 of 
patients with Fontan physiology tends to decline steeply during late 
childhood/adolescence and more slowly thereafter[21]. The decline 
in peak VO2 appeared to be due primarily to a decline in the oxygen 
pulse at peak exercise.  It was also associated with an increase in the 
VE/VCO2 slope during exercise.  Multivariate analysis revealed that 
progressive impairment of the chronotropic response to exercise also 
accounted for some of the decline in peak VO2.  
    The observed steep decline in peak VO2 during late childhood/
adolescence was attributed to the large increase in skeletal muscle 
mass that is associated with puberty. In normal individuals, this 
increase in muscle mass is accompanied by a commensurate increase 
in the ability to augment cardiac output (and oxygen delivery) during 
exercise. Consequently, peak VO2 (in mL/min) normally increases 
dramatically during the course of the adolescent years. However, 
unlike patients with normal, biventricular circulations, the Fontan 
patient’s ability to increase cardiac output during exercise is limited. 
The increase in peak VO2 that is normally associated with puberty 
is therefore attenuated; consequently, % predicted values decline. 
The authors also observed that the decline in peak VO2 is more 
pronounced among male subjects compared to female subjects, and 
attributed this observation to the fact that the increase in muscle 
mass associated with male puberty typically exceeds that associated 
with female puberty[21]. Giardini et al also analyzed serial exercise 
data from 53 patients with Fontan physiology. They too found a 
progressive decline in peak VO2[22]. In contrast, Nir et al reported that 
the exercise function of 25 patients who had undergone a Fontan 
procedure between 1977 and 1989 remained stable[23]. The initial 
peak VO2 of these patients from the early Fontan era was much 
lower than that reported in the more recent studies; this discrepancy 
probably accounted for the slower decline in Nir et al’s series.
    Kipps et al analyzed serial exercise data from 70 patients who had 
undergone repair of Tetralogy of Fallot. They found a small annual 
decline in %predicted peak VO2. The decline was very variable, 
however. Once again, it was strongly associated with a concomitant 
decline in the oxygen pulse at peak exercise.  An association between 
the decline in peak VO2 and a concomitant increase in the VE/VCO2 
slope was also observed. Statistically significant associations were 
not observed between the rate of decline of %predicted peak VO2 and 
numerous clinical, echocardiographic and CMR variables[24].
    In another study, Kipps et al also analyzed longitudinal exercise 
data of 23 patients with Ebstein’s anomaly. They observed a decline 
in %predicted peak VO2. The decline was steeper among patients <18 
years of age. A decline in the oxygen pulse accounted for most of the 
decline in peak VO2. Multivariate modeling revealed that a decrease 
in the heart rate at peak exercise also contributed to the decline in 
peak VO2[25]. 
   In 2004, Roos-Hesslink et al reported the results of serial exercise 
tests in 50 patients with d-TGA palliated by a Mustard procedure.26 
They found that the maximal exercise capacity of these patients 
averaged 84% of predicted in 1990 and declined to 72% of predicted 
in 2001. %Predicted peak heart rate did not decline during this time 
period. In contrast, Matthys et al detected no change in the exercise 
capacity during 6-17 years of follow-up in 16 patients who had 
undergone atrial switch procedures for d-TGA[27].
    Reybrouck et al reported the results of longitudinal exercise 
studies in 79 patients with a variety of congenital heart defects[28]. 
These authors found that the VO2 at the VAT of patients with simple 
defects, who were not restricted from physical activity, remained 
Figure 1 Effect of cardiac rehabilitation program on patients with 
congenital heart disease. Peak oxygen consumption rose in 15/16 subjects 
following cardiac rehabilitation; overall, oxygen consumption increased 
an average of 22% above baseline, pre-rehabilitation values. Pre: Pre-
rehabilitation; Post: post-rehabilitation (From: Rhodes J et al Impact of 
cardiac rehabilitation on the exercise function of children with serious 
congenital heart disease. Pediatrics. 2005; 116:1339-1345 From: Rhodes J et 
al Impact of cardiac rehabilitation on the exercise function of children with 
serious congenital heart disease. Pediatrics. 2005; 116: 1339-1345.)
Figure 2 Longitudinal exercise function of patients following the Fontan 
procedure. Each thin line represents the regression line of exercise tests 
from an individual patient. The thick lines represent the average of all 
patients’ regression lines before and after age 18 years. Percent predicted 
peak VO2 fell steeply prior to age 18; the decline was much more gradual 
thereafter. From: Fernandes SM et al Serial cardiopulmonary exercise 
testing in patients with previous fontan surgery. Pediatr Cardiol. 2010; 31: 
175-180.
    Several serial studies have documented acute improvements in 
the exercise function of patients with congenital heart disease have 
following participation in a formal exercise rehabilitation program 
(Figure 1)[16-19]. Sustained benefits (more than 6 months after the 
termination of the rehabilitation program) have also been observed 
in rehabilitation subjects, but not in a group of control subjects with 
similar congenital heart defects observed during the same period[20].
ReSuLTS of LongiTudinAL STudieS of 
exeRCiSe funCTion in CongeniTAL 
heART diSeASe
There exists in the literature only a small number studies that have 
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stable during the follow-up period. In contrast, patients with 
medically-imposed physical restrictions and/or significant residual 
hemodynamic lesions decreased significantly over time. In 2013, 
Muller et al reported the results of longitudinal exercise studies 
in 522 patients with a variety of congenital heart diseases. They 
observed a slow (1.01±6.83 percentage point/yr) decline in peak VO2 
that appeared to be independent of diagnosis, heart disease severity, 
systemic ventricular morphology or age. The decline appeared to be 
steeper among patients who had a pacemaker[1].
    In summary, longitudinal studies have provided interesting and 
potentially important insights into the natural history of exercise 
function in patients with repaired congenital heart defects. They have 
revealed that a gradual deterioration in exercise function is common. 
In many patients and for many defects, deconditioning probably 
accounts for some of the decline. Undoubtedly other lesion-specific, 
reversible and irreversible phenomena also contribute to this process; 
the exact role of each factor remains to be elucidated.  
    Other studies have found that congenital heart disease patients with 
poor exercise function have a much higher mortality risk than those 
with well-preserved exercise function[29-32]. The progressive decline 
in exercise function that has been observed in many longitudinal 
studies is therefore quite concerning. Are there any interventions that 
can effectively interrupt or reverse the decline in exercise function? 
Is a steep, sudden decline more concerning than a gradual decline? 
Serial exercise studies have demonstrated that various interventions 
can achieve acute, and sometimes sustained, improvements in 
exercise function. Will these improvements become associated with 
an improved long-term quality of life and a decreased mortality risk? 
Additional studies are needed to address these questions. 
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ABSTRACT 
Cardiopulmonary exercise testing is a valuable tool in the diagnosis 
and management of pediatric congenital heart disease. Parent and 
child reports of the child’s physical activity relative to peers are also 
routinely used to monitor heart function. Unfortunately, objective 
measures of their physical activity indicate that most children with 
congenital heart disease lead sedentary lives, which increase their 
risk of secondary morbidities. Current recommendations emphasize 
the need to proactively counsel patients to engage in at least 60 
minutes of physical activity daily. Information regarding the child’s 
current capacity for physical activity can be obtained through a 
physical literacy assessment and enhanced use of cardiopulmonary 
exercise results. Physical literacy is the knowledge, motivation, 
behaviour and physical competence needed to adopt and maintain a 
physically active lifestyle. Protocols to assess these physical literacy 
domains are well established, with the Canadian Assessment of 
Physical Literacy offering the first comprehensive assessment of all 
domains. Cardiopulmonary exercise protocols that incorporate sub-
maximal stages, and measures of the child’s willingness to perform 
maximal intensity exercise provide important information about 
the child’s capacity for physically active play with peers, which 
seldom requires a maximal effort. Measures of physical literacy 
and sub-maximal cardiorespiratory capacity thus provide important 
information when counselling children with congenital heart 
defects and their parents regarding the child’s daily physical activity 
participation.
© 2015 ACT. All rights reserved.
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InTRoduCTIon
Exercise testing has been a staple in the care of children with 
congenital heart defects for more than 25 years[1]. The gold standard 
exercise test throughout this time has been maximal exercise capacity, 
typically measured with a bicycle or treadmill protocol. Results from 
the maximal exercise test are reported as the percentage of predicted 
maximal oxygen consumption (VO2) achieved. The maximal exercise 
test provides important information about heart function, arrhythmias, 
and cardiac output during exercise[2]. Maximal exercise capacity is 
known to be associated with mortality and morbidity among children 
with corrected congenital heart defects[3].
    Currently more than 95% of children with non-critical and 70% of 
children with critical congenital heart defects survive to adulthood[4]. 
As such, clinical and research attentions have turned toward 
secondary morbidity and quality of life. Children with congenital 
heart defects are known to lead sedentary lifestyles[5] that persist into 
adulthood[6]. These sedentary lifestyles increase the risk for secondary 
morbidities such as hypertension, obesity, diabetes, and acquired 
heart disease[7]. Given the long-term implications of sedentary 
lifestyles for children with congenital heart defects, the American 
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Heart Association has published a scientific statement (May 2013) 
on the promotion of physical activity to individuals with congenital 
heart defects[8]. The AHA statement suggests that clinicians should 
proactively promote physical activity to all individuals with 
congenital heart defects during every clinical encounter, and that 
physical activity, fitness and motor skill should also be assessed. 
    Research among healthy individuals has demonstrated that 
moderate amounts of daily physical activity have a substantial 
impact on health and quality of life[9]. In order to optimize the health 
benefits of physical activity, international recommendations state 
that children should perform at least 60 minutes of physical activity 
daily[10-14]. Research with children with congenital heart defects has 
demonstrated that daily physical activity may be reduced even when 
maximal exercise capacity is age-appropriate[6,15-19]. As a result, an 
assessment that only measures maximal exercise capacity may not 
provide the information needed to appropriately counsel patients 
about physical activity or assess the risk of morbidities associated 
with a sedentary lifestyle.
A new ASSeSSmenT PARAdIgm
In order to optimize the long-term health and quality of life of 
children with congenital heart defects, a new assessment paradigm 
that optimizes the use of exercise test results to promote physically 
active lifestyles is recommended. The new paradigm would 
incorporate a variety of exercise assessments within two broad 
categories: (1) physical literacy; and (2) expanded use of the data 
available from a maximal cardiopulmonary exercise test. Assessment 
results from these sources can provide important information 
about children’s physical activity, and the barriers that limit their 
participation.
ASSeSSmenT of PhySICAl lITeRACy
Physical literacy is the attributes, skills, characteristics and behaviours 
that enable a physically active lifestyle[20]. Unlike traditional concepts 
of fitness or exercise capacity, physical literacy considers the impact 
of a much broader range of factors that may impact physical activity, 
such as motor skill, knowledge and understanding, motivation or 
daily behaviour. Taken together, physical literacy represents the 
child’s capacity to achieve and maintain a physically active lifestyle. 
The Canadian Assessment of Physical Literacy is a valid and reliable 
measure of the physical literacy of children 8 to 12 years of age. 
It provides an overall measure of physical literacy, as well as sub-
domain scores for motivation and confidence, knowledge and 
understanding, physical competence and daily behaviour[21]. The 
benefits and limitations of the Canadian Assessment of Physical 
Literacy are briefly summarized in figure 1. Detailed protocols are 
available at www.capl-ecsft.ca. Simple screening tasks, suitable for 
administration in healthcare settings, that can identify children who 
are struggling on their physical literacy journey are currently being 
evaluated (unpublished data). Comprehensive, valid and reliable 
protocols to assess a broad spectrum of physical literacy components 
among young children or adolescents have not yet been published, 
although individual protocols for specific aspects of physical literacy 
(e.g., accelerometry for daily behaviour, handgrip dynamometry for 
muscular strength) are available.
Assessment of Motivation and Knowledge
The concept of assessing a child’s motivation for physical activity 
often seems counterintuitive because most adults believe that 
children are naturally active. Parents will say that their children never 
sit still or that keeping up with their children is exhausting, and yet 
objective measures of their activity indicate that they spend their 
discretionary time in primarily sedentary pursuits[22]. We know that 
motivation, confidence and self-efficacy for physical activity are 
critically important to the physical activity participation of healthy 
children[23,24]. Youth with congenital heart disease indicate that 
physical activity is not a valued pursuit and experiences of exclusion, 
low self efficacy, fatigue and covert fears combine to further decrease 
physical activity motivation[25]. Research suggests that the severity of 
the cardiac defect does not have a direct effect on physical activity 
participation. Rather individual beliefs about self-efficacy for 
physical activity, the recommendations provided by the cardiologist 
and parental attitudes are of primary importance[26]. 
    A comprehensive assessment of the many facets of knowledge 
(activity opportunities, rules, skill development, recommended 
behaviours, etc.) and motivation (enjoyment, social support, 
adequacy, benefits, etc.) that influence childrens’ physical activity 
participation would be difficult to administer. There are many 
published questionnaires that assess motivation for physical 
activity, but most are designed for adults (e.g., RM 4-FM (Deci 
& Richard); Processes of Change (Marcus & Forsyth; Exercise 
Motivations Inventory (Markland); Physical Activity Enjoyment 
Scale (Kendzierski & DeCarlo)). Questionnaires specifically for 
children (Children’s Self-perceived Adequacy and Predilection for 
Physical Activity[27] often include assessment components specific 
to school physical education, rather than or in addition to the more 
general concept of physical activity. The questionnaire component of 
the Canadian Assessment of Physical Literacy (www.capl-ecsfp.ca) 
is designed to assess the physical activity knowledge and motivation 
of children 8 to 12 years of age. The questionnaire can be completed 
online, and automated scoring provides feedback regarding the 
child’s physical literacy knowledge and motivation. Most healthy 
children have knowledge and motivation levels that are lower than 
what is considered adequate for physical literacy. Preliminary data 
among children who have congenital heart defects indicate that they 
obtain similar results (unpublished data). 
    It is important that clinicians counselling children with congenital 
heart defects regarding physical activity consider the knowledge and 
motivation of the child, as well as the knowledge and motivation 
of significant adults who care for the child. Support for the child’s 
physical activity among immediate family members is very 
important, but the knowledge and motivation of other adults (e.g., 
teachers, day care providers, parents of other children) should also 
be considered. Developing sufficient motivation for physical activity 
and the acquisition of knowledge regarding appropriate physical 
activity opportunities are the foundation of the earliest stages of 
behaviour change[28]. Patients will begin to contemplate changing 
their physical activity behaviour only when they become aware of 
the need for change. In order to move from contemplation to the 
preparing for action stage, patients must develop sufficient motivation 
for physical activity and resolve any ambivalence towards a change 
in behaviour[28,29]. Clinicians should explore the child’s physical 
activity interests as well as the physical activity resources available 
when counselling patients and families. It is also helpful to introduce 
the child/family to a broad range of appropriate physical activity 
opportunities to ensure that a lack of knowledge or uncertainty about 
activity does not inappropriately restrict the child’s participation. 
Research indicates that over 40% (33/81) of parents of children 
with congenital heart defects have questions or concerns about their 
child’s physical activity participation (unpublished data).
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Assessment of Daily Behaviour
Asking patients about their physical activity participation is a well-
established practice in paediatric cardiology. Physicians inquire about 
the types of activity the child performs, whether the child can do as 
much physical activity as peers, and whether any symptoms occur 
with exertion. In relation to supporting children with congenital heart 
defects to achieve the physically active lifestyle associated with 
optimal health, this traditional approach has several limitations. First, 
it relies on child self- or parent proxy-reports of the child’s physical 
activity. Research has clearly demonstrated that subjective reports of 
physical activity participation are very inaccurate. There is low to fair 
agreement between parent and child reports of the child’s physical 
activity[30] and the reported physical activity levels differ significantly 
from objective measures[31]. Children considered inactive based on 
accelerometer measures of daily activity were reported to be active by 
80% of parents and 40% of the inactive children themselves[31]. Among 
patients with congenital heart disease, the inaccuracy of subjective 
estimates of exercise capacity has also been demonstrated[32,33] even 
among those who reported being asymptomatic[32]. An additional 
limitation is the use of peers as a reference for the child’s activity 
level. Studies provide conflicting evidence as to whether children 
typically achieve the recommended level of physical activity[22,34]. 
For North American children[22,35] at least, most healthy peers lead 
sedentary lifestyles such that “being able to keep up with peers” does 
not represent a physically active lifestyle.
    Pedometers and accelerometers are devices that measure walking 
steps or body acceleration, respectively. Pedometers provide a 
measure of the child’s physical activity, while accelerometers can 
measure both sedentary and active behaviours. Population-based data 
for typical values among children as well as recommended levels 
for optimal health are available for both types of measures. Children 
should accumulate at least 12,000 steps per day[36] or at least 60 
minutes per day of activity that is of moderate or higher intensity[10-14]. 
Accelerometers are considered more accurate, particularly for non-
walking activities, but they are also more expensive ($200-$400 
versus $10-$15 or less). More recently, pedometers that also estimate 
time spent in moderate-to-vigorous activity have been developed[37]. 
All of these devices are very small, making them suitable for even 
young children[38,39]. Most are water-resistant and are worn on the 
waist or wrist. Due to the high day-to-day and within-day variability 
of children’s physical activity, 7 days of pedometer or accelerometer 
measurements with the device worn for at least 10 hours per day are 
recommended[40], although physical activity can be estimated from a 
minimum of 4 days (including 1 weekend day).
    Objective measures of daily behaviour are valuable when 
counselling patients regarding physical activity because the data can 
dispel misconceptions about the child’s level of activity. Measures 
of sedentary time are typically very high, on average 7 to 8 leisure 
hours per day for adolescents[22]. Data on the high amount of 
discretionary time spent in sedentary pursuits can counteract the most 
commonly cited barrier to increasing physical activity – a lack of 
time. Even when very few children achieve the daily physical activity 
recommendation, most children will achieve the recommended 
activity level on at least 1 day per week[36]. These data can be helpful 
in counselling children and parents that achieving the recommended 
activity level is possible for children with a congenital heart defect. 
They also demonstrate the feasibility of the recommended behaviour 
change. Although children with congenital heart defects are often 
Motivation and 
Knowledge
Figure 1 Physical Literacy Assessment Paradigm.
1 CAPL questionnaire: motivation and knowledge components of the 
Canadian Assessment of Physical Literacy are available online (www.capl-
ecsfp.ca); 
2 Hay JA. Adequacy in and predilection for physical activity in children. 
Clin J Sport Med 1992;2:192-201.
3 CAPL assessment protocols are: obstacle course (motor skill), PACER 
shuttle run (aerobic endurance), hand grip dynamometry (muscular 
strength), plank isometric hold (muscular endurance), sit and reach 
flexometer (flexibility), body mass index (body composition).
Table 1 Examples of Health-Related Fitness Protocols (reprinted from 
Longmuir et al, 2013[8]).
Health-Related Fitness Dimension
Cardiorespiratory fitness
Flexibility
Muscular strength
Muscular endurance
Body composition
Examples of Assessment Protocols
20-metre shuttle run, 15-metre shuttle 
run, modified Canadian Aerobic 
Fitness Test.
Sit and reach, Back-saver sit and reach.
Handgrip strength, Standing broad 
jump, Vertical jump, Bosco jump 
protocol.
Plank static hold, Partial curl-up, Curl-
up, Bent-arm hang, Push-up.
Waist circumference, Body mass 
index, Waist-to-hip ratio, Sum of 
skinfolds.
Examples
CAPL Questionnaire1,
C h i l d r e n ’ s  S e l f -
perceived Adequacy 
and Predilection for 
Physical Activity2
Examples
Accelerometer or 
pedometer,
4+ days free living
Worn 10 hrs/day 
Examples3
Motor skill,
Aerobic endurance,
Muscular strength,
Muscular endurance
Flexibility,
Body composition
Daily Behaviour
Physical 
Competence
Advantages
• Identify motivation 
l i m i t a t i o n s  f o r 
activity;
•Recognize activity 
knowledge gaps;
• A s s e s s p h y s i c a l 
activity self-efficacy;
• Inform counselling 
approach to target 
appropriate avenues 
for change.
Advantages
• Accurate measure 
of activity compared 
to overestimates via 
self-report;
• Free-living activity;
• Direct comparison 
t o  p u b l i s h e d 
recommendations;
• S e d e n t a r y  a n d 
act ivi ty measures 
(accelerometer only).
Advantages
• Capacity for active 
childhood play;
• Ski l l re lat ive to 
peers;
•  I n j u r y  r i s k 
(strength/flexibility 
deficit);
• R i s k  f o r 
disordered eating & 
abnormal growth/
development;
• Functional capacity 
for activities of daily 
living.
Limitations
• K n o w l e d g e 
a s s e s s e d  f o r 
C a n a d i a n 
curriculum;
• Need for parent 
s u p p o r t  m a y 
l i m i t c h i l d r e n 
even if they are 
highly motivated.
Limitations
• Monitor must be 
worn and returned;
• Decreased accuracy 
f o r n o n - w a l k i n g 
activities;
• Substantial daily 
variation requires 3+ 
measurement days.
Limitations
• Normative data 
and recommended 
s t a n d a r d s  n o t 
available for some 
protocols;
• Isometric ef fort 
of musculoskeletal 
p r o t o c o l s  m a y 
increase afterload.
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sedentary[6,41], evidence that a physically active lifestyle is feasible 
for these patients can be seen in children with the most complex 
congenital heart defects who are able to achieve the recommended 
60 minutes of daily activity[19] even in the presence of significant 
limitations to maximal exercise. 
Assessment of Physical Competence
The physical competence domain within physical literacy refers to 
the motor skill, body composition and health-related physical fitness 
required to successfully participate in physical activity. Standardized 
protocols for assessing children’s health-related fitness (aerobic 
endurance, muscular endurance, muscular strength, flexibility) and 
body composition are well established (examples in table 1 and  Bar-
Or and Rowland, 2004[42]). Traditional assessments of motor skill 
are more limited because many established protocols are designed 
to identify children with motor skill deficits or to focus primarily on 
younger children[43-46], which may limit their usefulness in describing 
the motor skill of typically developing children[47]. The Canadian 
Assessment of Physical Literacy combines an obstacle course 
assessment of motor skill with health-related fitness assessments 
(PACER shuttle run[48] for aerobic endurance, plank isometric hold 
for muscular endurance[49], handgrip for muscular strength[50], sit and 
reach for flexibility[50], and height, weight and waist circumference 
for body composition[50]) to indicate the child’s physical competence 
for a physically active lifestyle. 
    Physical competence assessment results contribute valuable 
information when counselling children with congenital heart defects 
regarding a physically active lifestyle. The intermittent activity 
that characterizes the play of younger children[51] depends much 
more heavily on skill, strength, flexibility, and balance than aerobic 
endurance. Older youth also identify a perceived lack of skill as being 
a primary barrier to participation[25]. As such, the physical activity 
participation of children with congenital heart defects is typically 
not disadvantaged because of cardiac function or maximal exercise 
limitations, and even those with cardiac limitations can successfully 
participate[52]. In fact, some studies have suggested that children 
with complex heart defects may perform sub-maximal aerobic 
exercise as or more efficiently (i.e., with similar or lower levels of 
energy expenditure) compared to healthy peers[53,54]. Unfortunately, 
sedentary lifestyles, which are adopted by many children with 
congenital heart defects, are associated with decreased health-related 
fitness[55] and motor skill[56]. Thus, the decreased physical competence 
often observed among children with congenital heart defects is 
hypothesized to result primarily from their “hypoactive” lifestyles[6]. 
Fortunately, exercise training[57,58] and increased physical activity[59] 
can improve the fitness and motor skill of children with simple and 
complex congenital heart defects. 
enhAnCed uSe of CARdIoPulmonARy 
exeRCISe TeST ReSulTS
As summar ized by Rhodes and co l l eagues [2], max imal 
cardiopulmonary exercise tests provide important information 
regarding the cardiopulmonary function of patients with congenital 
heart defects. Most directly, these maximal effort tests indicate the 
child’s capacity for high intensity physical activity. However, the 
physiological changes that occur in response to an exercise stimulus 
can also provide important information regarding cardiovascular 
status, such as the response to changing vascular pressures, heart 
rate limitations due to sinus node dysfunction, or the impact of 
ventricular dysfunction, residual shunts or valvular disorders[2]. When 
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interpreting test results, it is important to determine whether the 
highest values attained represent a truly maximal effort (and therefore 
represent the individual’s maximum cardiorespiratory capacity) 
or simply the peak voluntary effort that was generated during the 
assessment. Maximal exercise capacity is primarily (40% to 70%) 
influenced by genetics[60]. Established criteria for a maximal effort in 
children include a plateau in oxygen consumption despite increased 
workload (which only occurs in about 50% of children), a heart rate 
of at least 195 beats/minute, a blood lactate concentration of 9 mmol/
litre or a respiratory gas exchange ratio that exceeds 1.0[42]. 
    While information on the function of the cardiovascular system 
during maximal exercise is beneficial for disease management, 
the health benefits of daily physical activity accrue with moderate 
intensity activity[11,13]. Thus, cardiopulmonary exercise protocols 
that incorporate sub-maximal exercises stages of at least 3 minutes 
duration (e.g., Bruce treadmill protocol) can provide important 
information to enhance physical activity counselling even in the 
absence of a maximal effort. Normative data for the heart rate 
response of children at each stage of the Bruce protocol[61] provide 
important information regarding the child’s capacity for daily 
physical activity and active play with peers. Sub-maximal exercise 
response is also an effective way to monitor the effects of training 
over time, as the energy and effort required for a given workload will 
decrease as physical fitness improves even in the absence of changes 
to maximal exercise capacity. The target activity intensity to increase 
cardiorespiratory fitness in children is an intensity of 60% to 80% of 
maximal exercise capacity[42]. Children as young as 7 years of age can 
be taught to monitor and maintain their target exercise intensity based 
on perceived exertion[62]. When counselling children with congenital 
heart defects and their families, it is important to educate families 
on the differences between maximal and typical exercise, as well as 
how the child’s capacity is suited for the typical energy demands of 
childhood physical activity[42,63].
ConCluSIon
Physically active lifestyles are important for the physical and mental 
health of children with congenital heart defects. Exercise assessments 
should include measures of physical literacy, as well as sub-maximal 
cardiorespiratory capacity. These results provide a more accurate and 
comprehensive picture of the child’s capacity for a physically active 
lifestyle, and are the foundation for providing effective physical 
activity counselling to the child and family.
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ABSTRACT
A 66-year old woman was admitted with typical clinical signs of 
angina pectoris. In her history only a chronic rheumatoid arthritis, 
treated through Adalimumab was reported. The electrocardiograph 
(ECG) showed sinus rhythm with terminal negative T-waves in V1-
V6 without any ST-elevations. Laboratory tests revealed a positive 
Troponin-I level and the transthoracic echo showed a reduced left 
ventricular (LV)  function by apical akinesia. We immediately 
performed cardiac catheterization to rule out the suspected 
coronary artery disease and documented surprisingly a Tako-Tsubo 
Cardiomyopathy with severe reduced LV function and signs of apical 
ballooning. Personnel distress, feeling of severe pain, any kind of 
anger, or anxiety could not be stated in the case history. A further 
invasive electrophysiological testing ruled out arrhythmias as trigger 
mechanisms for the Tako-Tsubo Cardiomyopathy. We stopped the 
Adalimumab therapy and could directly illustrate improved LV 
function to the normal status under resolved healthy conditions. 
This is the first time to report Adalimumab as cause for Tako-Tsubo 
Cardiomyopathy while there is to date literally no direct effect of 
TNF-alpha antibodies on the myocardium published - lacking any 
sympathetic nervous stress.
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LEARNING OBJECTIVES
The new TNF-alpha antibody Adalimumab - given to treat rheuma-
toid Arthritis may causes Tako-Tsubo Cardiomyopathy.
INTRODUCTION  
Tako-Tsubo Cardiomyopathy is a cardiac distress syndrome triggered 
through sympathetic nervous stress like anger, anxiety, pain, 
dyspnoea[1] or others[2]. Due to the reversible manner of the disease, (1) 
all findings resolve without further specific treatment[2] and (2) there 
are only betablockers established to reduce the recurring occurrence 
of the disease[3]. In the literature, other mechanisms are described 
triggering Tako-Tsub Cardiomyopathy. i.e. patients applied with 
Trastuzumab  or with immunglobulines[4]. Here, first and exclusively, 
we are demonstrating a new tumor necrosis factor-alpha antibody 
(TNF-alpha antibody: Adalimumab) as potential trigger for Tako-
Tsubo Cardiomyopathy lacking any sympathetic nervous stress. 
CASE REpORT
A 66-year old woman was admitted to the hospital with typical 
pressure pain on the left chest as well as tenderness on palpitation 
since 3 days. Historically, she is suffering a chronic rheumatoid 
arthritis set on Adalimumab [40mg subcutaneously per 2 weeks, 
tumor necrosis factor-alpha (TNF- alpha)-antibody] given second 
time, 3 days prior to admission as well as on Methotrexat (10 mg per 
week) linked by Hydrocortisone (5 mg daily) in remission phase. 
Distress situations were declined: there is no history of personnel 
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stress, anger, pain, dyspnoea, or anxiety. Further, no tachycardia 
could be reminded. 
    Clinically we found a woman in a good general condition and 
normal nutritional status, awake, oriented, her blood pressure 
120/70mmHg, her pulse 62/min., her respiratory rate was normal, 14/
min., oxygen saturation of 97%, no pathologic murmurs, auscultation 
of the lungs reveals no bilateral wheezes and rales, unobtrusive 
physical examination. Auscultation of the heart revealed normal 
findings.
    Laboratory tests resulted positive for troponin I (0.78ng/m), other 
laboratory values (particularly inflammation parameters) were within 
normal range. The electrocardiographic (ECG) showed a sinus 
rhythm at the rate of 62/min., terminal negative T waves in V1-V6 
as well as remarkable (non Pardee-Q) Q-waves in III, aVF (Figure 
1). X-ray of chest revealed complete normal. The transthoracic 
echocardiography showed reduced left ventricular function, ejection 
fraction was determined to 40% using Simpson’s equation with 
akinetic apical walls of all regions (Figure 2). In respect to the 
supposed non-ST-elevation myocardium infarction (NSTEMI), we 
immediately performed an invasive cardiac catheterization to rule 
out the suspected coronary artery disease. All coronary arteries were 
inconspicuous, clean and smoothly perfused (Figure 3). Further, 
we illustrated severe reduced left ventricular function with signs of 
typical ballooning in respect to Tako-Tsubo Cardiomyopathy (Figure 
4). Clinically, the tenderness on palpitation as well as the signs of 
“cardiac memory” in the ECG resisted both, so that we were forced to 
rule out further arrhythmias as trigger mechanisms for the identified 
Figure 1 ECG of the Patient during admission. Shown here is the regular 
sinus rhythm at the rate of 62/min., terminal negative T-waves in V1-6 
and Q-waves in III, aVF as demonstrated in respective ECG’s.
Figure 3 Coronarangiography of the left coronary arteries. Invasive cardiac 
catheterization was performed. The contrast enhanced angiography (10ml 
Imeron 350, applied manually) of the left coronary artery systems reveals 
inconspicuous, clean and smoothly perfused arteries. The right coronary 
artery looked the same (data not shown). The coronary artery disease 
could be rule out completely. Here frozen in diastole.
I
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
Figure 2 Transthoracic Echocardiography. Shown here is the typical 
apical four-chamber view frozen in systole with reduced left ventricular 
function, ejection fraction measured to 40% (Simpson) and apical akinesia.
Figure 4 Left Ventriculography. Invasive cardiac catheterization was 
performed as mentioned above (see figure 3). The contrast enhanced left 
ventriculography (pressure guided application: 10ml/sec; volume of 
Imeron 350: 25ml) revealed the typical apical ballooning for Tako-Tsubo 
Cardiomyopathy. Here frozen in systole.
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Tako-Tsubo Cardiomyopathy. We performed an electrophysiological 
examination with normal, inconspicuous findings.
    Further examinations (holter ECG to rule out unidentified 
arrhythmias, the sonography of the complete abdomen; the gastroscopy 
and the coloscopy) were completely without any pathological findings.
    We suggested Adalimumab as trigger for the Tako-Tsubo 
Cardiomyopathy and stopped immediately the treatment. Therefore, 
we increased Methotrexat to 20 mg per week resolving the symptoms 
and improved left ventricular function to the normal status without 
any further regional wall motion irregularities. Finally, the patient 
was under healthy and stable condition at discharge.
DISCUSSION
Tako-Tsubo Cardiomyopathy is a cardiac distress syndrome 
triggered through sympathetic nervous stress like anger, anxiety, 
pain, dyspnoea[1] or others[2]. Clinically, patients with Tako-Tsubo 
Cardiomyopathy suffer acute chest pain, dyspnoea, or cardiac 
syncope leading to specific disease related alterations in ECG 
(ST elevations or terminal negative T-waves), in transthoracic 
echocardiography (apical hypo- to akinesia), or in invasive cardiac 
catheterization (left ventricular dysfunction with apical ballooning, 
and no signs of coronary artery disease). Cardiac myocardial markers 
as Creatininkinase or Troponin I show increased levels typical for 
the pathological mechanism behind the Cardiomyopathy: reversible 
myocardial sympathetic nervous stress with additional catecholamine 
overload of the left ventricular[5,6]. 
    Due to the reversible manner of the disease, (1) all findings 
resolve without further specific treatment[2] and (2) there are only 
betablockers established to reduce the recurring occurrence of the 
disease[3]. A general treatment suggestion is the reduction of psychic 
stress for the patient[1]. Further, (3) in cardiac shock, only intra-
aortic pulsation treatment is established to secure the left ventricular 
function while catecholamines have to get discontinued[7].
In the literature, other mechanisms are described triggering Tako-
Tsub Cardiomyopathy. i.e. patients applied with Trastuzumab or with 
immunglobulines[4]. Here, first and exclusively, we are demonstrating 
a new tumor necrosis factor-alpha antibody (TNF-alpha antibody: 
Adalimumab) as potential trigger for Tako-Tsubo Cardiomyopathy 
lacking any sympathetic nervous stress. 
     This is a new human monoclonal antibody[8] binding to the 
TNF-α antigen and is established in chronic rheumatoid arthritis[9]. 
Side effects are opportunistic infectious diseases. In respect, contra 
indications are active tuberculosis, or sarcoidosis, as well as heart 
failure NYHA III-IV[10,11].
    The chronic inflammatory disease rheumatoid arthritis (RA) 
assesses primarily articulations and secondarily extra-articular 
systems like i.e. the cardiovascular system[12]. The grade of 
inflammatory activity of the rheumatoid arthritis is known as 
established risk factor for coronary atherosclerosis. This increased 
risk may be attributable to RA-specific risk factors such as 
hyperhomocysteinemia, disease-related dyslipidemia or vascular 
inflammation, or to morbidity related to medications and high levels 
of TNF-alpha. The possible roles of TNF-alpha in the development 
of atherosclerosis include the recruitment of inflammatory cells to 
the site of injury or the promotion of adverse vascular smooth muscle 
cell remodelling. TNF-alpha may also act as a proinflammatory 
factor in plaque rupture[13]. 
    In contrast, Anticytokine therapy could prove beneficial in the 
treatment of patients with heart failure[13]. While early studies 
supported this hypothesis, anti-TNF strategies have not demonstrated 
salutary benefits in large multicenter randomized and placebo-
controlled clinical trials in patients with symptomatic heart failure[13]. 
There is a variety of possible explanations for the failure of anti-
TNF therapy: (1) TNF antagonism has untoward effects in the setting 
of heart failure; (2) the biological agents used in the trials were 
intrinsically toxic; (3) sex and race may have important implications 
in the outcome after anticytokine therapy; (4) the TNF-alpha protein 
contains a polymorphism, and, in fact, genoma plays a role in 
modifying the pharmacologic response to anticytokines; (5) anti- 
TNF-alpha approaches could have had pharmacodynamic interactions 
with other heart failure medications; and (6) the patients in these trials 
may have been inappropriately selected. These disappointing results 
may determine controversial attitude in the long-term treatment with 
anti-TNF agents in RA[14].
     The effects of TNF-alpha blockers on incident cases of congestive 
heart failure (CHF) in RA are controversial. Here, in this case, the 
disease was steady-state in remission under immune suppressed 
therapy [chemically in the blood test no signs of active inflammation]. 
In the transthoracic echo we ruled out pericardial or myocardial 
involvement while left ventricular function got resolved to a normal 
staus by discontinuation of TNF-alpha antibody treatment. Direct 
TNF-alpha effects on the left ventricular function are to disclose[13]. 
Further, the ventricular function was primarily normal and got 
completely resolved (improved) after the acute/ active phase of the 
disease (Tako-Tsubo Cardiomyopathy). In general, the following 
suggestions were established through the guidelines for the treatment 
of RA: (1) RA patients with history of CHF and a concomitant 
indication for the use of TNF-alpha blockers do not need a baseline 
cardiac evaluation to screen for heart failure; (2) patients with well-
compensated mild CHF New York Heart Association (NYHA) 
classes I and II and a concomitant indication for the use of TNF-
alpha blockers should be evaluated at baseline and then be closely 
monitored for any clinical signs of worsening heart failure; and (3) 
patients with (NYHA) class III or IV heart failure should not be 
treated with TNF-alpha blockers in any case[14].
CONCLUSION  
Adalimumab, a new TNF-α antibody, applied in chronic rheumatoid 
arthritis may directly trigger Tako-Tsubo Cardiomyopathy without 
any sympathetic nervous stress. Hence, monitoring of either clinical 
symptoms (palpitations) or the left ventricular function [through 
transthoracic echocardiography] is indicated while Adalimumab is 
applied. When Tako-Tsubo Cardiomyopathy occurs, the immediately 
discontinuation of the treatment with Adalimumab resolves left 
ventricular function and clinical symptoms. 
    However, it would be ambitious to conclude from a single case 
observation that Adalimumab causes Tako-Tsubo Cardiomyopathy. 
The authors hereby recommend a clinical trial to test this hypothesis 
in a multi-center fashion.
     Sympathetic nervous stress is widely known as trigger for Tako-
Tsubo Cardiomyopathy. However, the increasing number of other 
findings (like i.e. Adalimumab) as pathological mechanism triggering 
Tako-Tsubo Cardiomyopathy suggests the need for further studies of 
this specific disease. 
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ABSTRACT
A 46 year old female Caucasian was admitted with shortness of 
breath on exertion, productive cough and hemoptysis few days of 
duration without any other chronicle diseases. She had recent history 
of sigmadiverticulitis treated with antibiotic and hysterectomy a year 
ago because of hypermenorrhoe. Vital signs were stable without any 
clinical signs of a deep venous thrombosis. The electrocardiogram 
(ECG) showed sinus rhythm with an incomplete right bundle branch 
block. Laboratory tests revealed a negative d-dimer (Latex-method). 
We assessed a contrast enhanced computed tomography scan (CT) 
of the chest illustrating surprisingly a severe pulmonary embolism 
in the right lung (main bronchus of the lower lob). Several further 
examinations ruled out malignant diseases or favorable thrombosis. 
Treatment of the patient was established using low molecular weight 
heparin (subcutaneously administered), switched to rivaroxaban at 
the end of the in-hospital duration. Discharge was carried out after 
eight days in stable conditions. Anticoagulation was prescribed 
for three months. D-dimer testing is clinically established to rule 
out embolism/thrombosis laboratorial despite of arterial or venous 
location. This is a unique case, where the laboratorial testing failed 
to detect a severe pulmonary embolism while the sensitivity for 
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the d-dimer testing tends in general high. Clinically, the imaging 
approach (computed tomography scan of the chest) reflects “the gold 
standard” for pulmonary embolism in contrast to the d-dimer testing.
© 2015 ACT. All rights reserved.
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INTRODUCTION
Due to the high sensitivity of the d-dimer-test[1] - in general, 
the d-dimer test is used to demonstrate the specific diagnosis of 
pulmonary embolism or deep vein thrombosis[2]. In contrast, a 
negative d-dimer-testing rules out severe pulmonary embolism 
in high probability[1,2]. Here in this specific case report, we are 
demonstrating a 46 year old female Caucasian suffering acute severe 
pulmonary embolism identified through thoracic CT without elevated 
d-dimer levels in the laboratory. This case is important and needs to 
be reported due to the lack of elevated d-dimer testing even when 
severe pulmonary embolism occurred.
CASe RepORT
A 46 year old female Caucasian was admitted with shortness of 
breath on exertion, productive cough and hemoptysis since few days 
without any other chronical diseases. She had recent history of sigma 
diverticulitis treated with antibiotic and hysterectomy a year ago 
because of hypermenorrhoe. Patient was still active on nicotine (2 
pack years). Orally informed consent was obtained from the patient 
for publication of this case report and any accompanying images.
    Clinically we found a woman in a good general condition and 
normal nutritional status, awake, oriented, her blood pressure 100/70 
?????????????? ???????????????????
mmHg, her pulse 62/min, her respiratory rate increased 21/min, 
oxygen saturation of 97%, no pathologic murmurs, auscultation of 
the lungs reveals no bilateral wheezes and rales, unobtrusive physical 
examination.
    Laboratory tests resulted negative for d-dimer-testing three times 
with the Latex-method (0.28/0.33/0.45), other laboratory values were 
within normal range. The ECG showed a sinus rhythm at the rate of 
62/min., incomplete right bundle branch block, without excitation 
abnormalities (Figure 1). X-ray of chest revealed the contour of a 
diaphragm in regular and deep standing manner, compatible with 
a pulmonary emphysema, no pneumonia, mediastinum wasn't 
widened, no stasis and enlargement of the heart, aorta was according 
to age. The transthoracic echocardiography was completely with 
normal findings. For further acute analysis, we performed a contrast 
enhanced CT-scan of the chest and figured out an embolism of the 
pulmonary artery of the lower lobe without infarction, without round 
lesions or enlargement of the lymph nodes (Figure 2). 
    Further examinations (the sonography of deep veins and of 
complete abdomen; gynecological examination; the CT-scan of 
the abdomen; the gastroscopy and the coloscopy) were completely 
without any pathological findings except for diverticulosis without 
signs of acute activation, two hemangiomas in the liver, a liver cyst 
in the left liver lobe.
    The appropriate treatment for this patient without cardiovascular 
instability was anticoagulation with low molecular weight heparin, 
which was subcutaneously administered during the several 
examinations. During the in-hospital duration we switched the 
anticoagulation therapy to rivaroxaban per oral[3]. Hospital discharge 
was carried out after eight days in stable condition. 
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Figure 1 ECG of the Patient during admission. Shown the regular sinus 
rhythm at the rate of 62/min., incomplete right bundle branch block, 
without excitation abnormalities as indicated in respectively ECG’s.
Figure 2 Contrast Enhanced CT-Scan of  the Chest. Pulmonary embolism 
detected in the main bronchus of the lower lob of the right lung without 
signs of infarction, infiltrations or tumors. The black arrow marks the 
thrombosis in the right lower bronchus.
DISCUSSION
D-dimer is a fibrin degeneration product and is generated during a 
fibrinolysis reflecting a diagnostic method for assessing coagulation 
activity[4]. Several independent methods to measure the d-dimer 
activity (quantitative production of d-dimer) such as ELFA, ELISA, 
Latex- and whole blood assays (Table 1) are established[5]. D-dimer-
testing is used in the diagnosis of suspected thrombotic disorder (deep 
venous thrombosis, pulmonary embolism, disseminated intravascular 
coagulation) (Table 2). A negative d-dimer-test is clinically reducing 
the probability of thrombotic disorder in patients without severe 
diseases, anticoagulation therapy, recent surgery and pregnancy[4]. 
In addition there are many causes of quantitative high-level of 
d-dimer for example: heart diseases, heart attack, pneumonia, cancer, 
advanced age and infectious diseases (Table 2)[6]. 
    A pulmonary embolism is caused through an embolus in the 
pulmonary artery due to (i) high degree of coagulation[7], high degree 
of cardiac thrombosis[7] or high degree of endothelial disorders of 
the pulmonary arteries[7,8]. A blood gas analysis in patients with 
pulmonary embolism shows hypoxemia and hypokapnia[9]. The ECG 
shows signs of right sided ventricular strain, SIQIII-type, complete 
right bundle branch block[10]. A contrast enhanced CT-scan of the 
chest is a special diagnostic method to find pulmonary embolisms 
with a sensitivity of 86-100%[11]. This disease is the most common 
unrecognized cause of death[9]. Approximately 95% of pulmonary 
embolisms derive from thrombosis in the vena cava inferior[1]. 
Typical clinical signs are: dyspnea/ tachypnea, tachycardia, cyanosis, 
chest pain, cough, hemoptysis, dizziness, sweating, syncope (in the 
short term)[12] The clinical condition ranges from asymptomatic to 
I
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
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Method
Immunofluorescence immunoassay
Immunoadsorption assay
  microplate immunoassay
  membran-immunoassay
Latex-method
Whole blood assay
Table 1 Systems for d-dimer testing.
Type
ELFA
ELISA
Manufacturer
VIDAS®
Asserachrom®
NycoCard®
Cardiac Reader®
Instant IA®
Tinaquant®
STA-lia-test®
HemosIL
SimpliRed®
Simplify®
aortic aneurysm
other vascular aneurysm
hemangiomas
Kasabach-Merritt-Syndrome
other vascular malformation
several shunts
malignancies in particular adenocarcinoma
several hematological cancer
venous or arterial thrombosis
pulmonary embolism
peripheral or coronary arterial embolism
trauma
recent surgery
burns
hematoma
aortic dissection
sepsis
severe infections
erysipelas
HELLP-syndrome
hemolysis
HIT type2 (heparin-induced thrombocytopenia)
Table 2 Causes of elevated d-dimer levels.
Permanently increased 
values in blood
 
 
 
 
 
 
 
Acute increased 
values in blood
 
threatening condition in cardiac shock[12]. There are several risks 
of pulmonary arterial embolisms: immobility, previous trauma, 
operations, smoking, varicose veins, congestive heart failure, 
female gender, pregnancy, contraceptives, obesity, advanced age, 
drying out and rare vascular anomalies[12]. If there is a presence of 
recurrent thrombosis pathological findings such as antiphospholipid 
syndrome, protein C and S deficiency ATIII-deficiency, polyglobulia, 
polycythemia vera and malignant diseases should be ruled out[6].
    Due to the high sensitivity of the d-dimer-test[1] - in general, 
the d-dimer test is used to demonstrate the specific diagnosis of 
pulmonary embolism or deep vein thrombosis[2]. Thereby, a negative 
d-dimer-testing rules out severe pulmonary embolism in high 
probability[1,2]. 
CONClUSION  
Because of the high incidence of early lethality in patients with acute 
pulmonary embolism reflecting clinically symptoms such as dyspnea/ 
tachypnea, tachycardia, cyanosis, chest pain, cough, hemoptysis, 
a fast resolving therapy is very important. Therefore, clinically we 
demand an individual diagnostic concept. D-dimer-test is broadly 
used to determine pulmonary embolism or deep vein thrombosis. A 
negative d-dimer-testing rules out a severe pulmonary embolism with 
high probability[2]. Additionally, the sensitivity of the d-dimer-test 
depends on the used diagnostic method (Table 1) or further malignant 
and infectious diseases (Table 2). 
    Hence, we suggest primarily an imaging diagnostic method (CT 
scan of the chest) to determine pulmonary embolism in regard to the 
irregularities in the quantitative determination of d-dimer levels. A 
d-dimer-test alone is not sufficient.
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ABSTRACT
Thrombus distribution is known part of atrial arrhythmias. We 
here report a clinical example using cardiac 256-multidetector row 
computed tomography (256 MDCT) for examination to assess for 
small intracoronary thrombotic structures in proximal parts of vessels 
with either big size (> 2,5 mm diameter) and/ or existing bare metal 
stents on a 70 years old male individual. He was suffering a non 
ST elevated myocardial infarction due to intracoronary thrombus 
in bare metal stents in the proximal left artery descending (LAD) 
in regard to occult atrial fibrillation. Philips 256 iCT documented 
the small amount of rest thrombus after abciximab pre treatment 
before discharge of the patient under acetylsalicylacid (100mg) 
and phenprocoumon (for 6 months). Summarised, this example 
proposes and underlines further use of cardiac MDCT for patients 
with acute chest pain to improve prognostic outcome by reduction 
of complications. Additionally, even 3 years after bare metal stent 
implantation in big vessels, here proximal LAD, we are mainly 
demonstrating the need of continuous antithrombotic acetylsalicylacid
treatment to avoid in-stent thrombosis.
CASE REPORT
Cardiac Computed Tomography for Detecting Intracoronary 
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LeARning OBjeCTive
Further use of Cardiac CT is the detection of intraluminal thrombotic 
material in coronary stents.
CASe RepORT
A 70 years old male patient in good health conditions with known 
coronary artery disease
and existing three bare-metal stents (Cobalt-Chronium “Multi-
Link Vision Bare-Metal Coronary Stent System, 3.0×12mm, 
Abbott, Wiesbaden, Germany) in the proximal and mid part of the 
left anterior descendents artery (LAD) implanted 3 years ago, was 
presented to the Department for Cardiology with acute chest pain 
for 2 hours following chemically a Non-ST-Elevated Myocardial 
Infarction (NSTEMI).
    In the past, a common drug treatment was established with 100 mg 
acetylsalicylacid per day, 2.5 mg bisoprolol per day, 10 mg ramipril 
per day, 20 mg simvastatin per day and for 4 weeks clopidogrel 
7 5mg per day after bare-metal stent-implantation. The 100 mg 
acetylsalicylacid treatment was discontinued due to an elective 
surgery on the right carotid artery interna 2 weeks before hospital 
presentation in regard to severely stenosis.
    Actually, the Troponin I level raised to 1.5 ng/mL (normal < 0.05ng/
?????????????? ???????????????????
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mL) and the ECG demonstrated an paroxysmal atrial fibrillation 
turning in normal ventricular frequency (to this date unknown). 
Immediately, an invasive coronary angiography was performed and 
the coronary status was assessed revealing a remarkable structure in 
the proximal two stents of the LAD suspected to an intracoronary 
thrombus while normal perfusion was determined in all stents and the 
rest of the vessel (TIMI 3), see figure 1 (pre, marked through white 
arrows).
    Due to an intraluminal reduction of only 30% Diameter Stenosis 
in both proximal LAD stents, abciximab adjusted to the body 
weight was given intravenously for 12h and a second look was 
assessed using Philips iCT Cardiac 256-MDCT while the patient 
spontaneously converted into normal sinus rhythm (Figure 2). 
Retrospective gating to 75% RR interval was performed (heart rate 
65 beats per minute) and only a small rest thrombus in the proximal 
LAD stent surrounded by non- and calcified plaques as well as the 
struts of the both “Vision” stent systems (only 0.0032" thick) were 
observed (see bold white arrow, figure 2). The complete vessel 
demonstrated further almost inconspicuous perfusion. Caused 
through additional unspecific symptoms of the patient, we performed 
a second invasive coronary angiography with complete normal 
perfusion in all LAD stents (proximal and mid) and ruled out further 
intravascular thrombotic materials, see figure 1 (post).
    The patient got discharged 2 days later set on Phenprocuomon 
for 6 months due to stable sinus rhythm improved by beta-
receptor inhibition (metoprolol 95 mg per day) added to 100 mg 
acetylsalicylacid per day.
Figure 1 Invasive Coronary Angiography. Demonstrated here are slides from the invasive coronary angiography determining the intracoronary thrombotic 
structure in the two bare metal stents (Multi Link Vision Coronary Stent System, 3.0x12mm, Abbott, Wiesbaden, German) in the proximal left anterior 
descendents artery (LAD) as marked with white arrows. The upper panel (pre) shows the coronary status of the LAD in different ankles (LAO90°, RAO35° 
and LAO40°) as well as of the circumflex artery right after administration of the patient in the Department for Cardiology 2 hours after begin of symptoms 
(acute chest pain). The lower panel is demonstrating the coronary status after intravenous support of abciximab for 12 hours (post) in same angiographic 
ankles.
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DiSCuSSiOn
While thrombus distribution is known part of atrial arrhythmias[1-4], 
this example reveals cardiac 256-multidetector row computed 
tomography (256 MDCT) as clinical examination to explore small 
intracoronary thrombotic structures in proximal parts of vessels 
with either big size (> 2,5 mm diameter) and/or existing bare metal 
stents[5].
    The thrombotic structure in the LAD stents is caused through 
the discontinuing of 100 mg per day acetylsalicylacid treatment. 
The obviously distribution of the thrombotic material in the vessel 
is focusing mainly in the stent regions which excludes coronary 
embolisms through atrial arrhythmias as reason for the intraluminal 
thrombus.
    We support a further use of cardiac CT detecting intraluminal 
thrombotic material following (1) coronary calcium scoring[6], (2) 
coronary plaque formations[7-9], (3) coronary artery disease[10,11], 
(4) left ventricular function (mass, regional wall motions, ejection 
fraction)[12,13], (5) right ventricular function[14], (6) valve function 
(aortic valve)[15], and (7) the detection of the culprit lesion in 
myocardial infarction[16-18].
    Infusion of abciximab as antithrombotic treatment regimen is part 
of the drug management in acute coronary symptoms[19-22]. Here, 
partial success for thrombus lysis was assessed detected through 
cardiac 256-MDCT while even complete thrombus abolishment was 
assumed using conventional invasive coronary angiography (see 
figure 1, lower panel.).
?????????????? ???????????????????
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Figure 2 Cardiac 64-MDCT. Retrospektives Gating in 75% RR interval, heart rate 65/min in sinus rhythm revealed 12 hours after abciximab treatment 
demonstrated slides exploring small dark structure suspected for rest thrombotic material as marked with white arrow in the proximal LAD stent (marked 
with white lines). A. Demonstrated here are computer based reconstruction of strengthen LAD vessel (lower panel, axial cut) with the three stents (white 
lines) and the suspected thrombotic material (dark structure, marked with white arrow). In the upper panel, cross axial cuts are demonstrating only the 30% 
Diameter Stenosis caused through the thrombus in the LAD stent. B. Coronary curved section cuts demonstrating reconstructed contrast perfusion in the 
LAD. Highlighted here are the three stent positions (left panel, white arrows) and the 3D reconstruction with the red coloured marked LAD (right panel).
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